Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Lidia Mak"'
Autor:
Patricia Ohana, Yasmine Amitay, Lidia Mak, Hilary Shmeeda, Jenny Gorin, Alberto A. Gabizon, Dina Tzemach
Publikováno v:
Cancer drug resistance (Alhambra, Calif.). 4(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::900cafd5344973f035b57aea3c99982a
https://pubmed.ncbi.nlm.nih.gov/35582027
https://pubmed.ncbi.nlm.nih.gov/35582027
Autor:
Patricia Ohana, Yogita Patil, Lidia Mak, Hilary Shmeeda, Alberto Gabizon, Jenny Gorin, Yasmine Amitay, Dina Tzemach
Publikováno v:
Pharmaceutical Research. 33:686-700
Pegylated liposomal (PL) mitomycin C lipid-based prodrug (MLP) has recently entered clinical testing. We studied here the preclinical pharmacology of PL-MLP. The stability, pharmacokinetics, biodistribution, and other pharmacologic parameters of PL-M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::657f9bb7a802d733255e7636ce30c8c3
https://doi.org/10.1007/s11095-015-1819-7
https://doi.org/10.1007/s11095-015-1819-7
Autor:
Stephan T. Stern, Alberto Gabizon, Yasmine Amitay, Lidia Mak, Hilary Shmeeda, Yechezkel Barenholz, Jenny Gorin, Dina Tzemach
Publikováno v:
Journal of drug targeting. 24(9)
We developed a pegylated liposome formulation of a dissociable salt of a nitrogen-containing bisphosphonate, alendronate (Ald), coencapsulated with the anthracycline, doxorubicin (Dox), a commonly used chemotherapeutic agent. Liposome-encapsulated am
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cacb2b062c619ae146eb2365c54f1cb9
https://pubmed.ncbi.nlm.nih.gov/27187807
https://pubmed.ncbi.nlm.nih.gov/27187807
Autor:
Dina Tzemach, Jenny Gorin, Lidia Mak, Hilary Shmeeda, Samuel Zalipsky, Yasmine Amitay, Alberto Gabizon
Publikováno v:
Cancer Chemotherapy and Pharmacology. 66:43-52
The folate receptor (FR) is overexpressed in a broad spectrum of malignant tumors and represents an attractive target for selective delivery of anti-cancer agents to FR-expressing tumors. Targeting liposomes to the FR has been proposed as a way to en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b1f96d7e1a7c0b65a19924f2651f97
https://doi.org/10.1007/s00280-009-1132-4
https://doi.org/10.1007/s00280-009-1132-4
Publikováno v:
Journal of Controlled Release. 136:155-160
Background Receptor-directed targeting of ligand-bearing liposomes to tumor cells may enhance therapeutic efficacy by intracellular delivery of a concentrated payload of liposomal drug. The goal of this study was to assess whether Her2-targeted pegyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::342c673eb9426a6fc7a38d996ec389b3
https://doi.org/10.1016/j.jconrel.2009.02.002
https://doi.org/10.1016/j.jconrel.2009.02.002
Autor:
Yasmine Amitay, J. Allen Zhang, Dina Tzemach, Alberto Gabizon, Lidia Mak, Hilary Shmeeda, Kumar Saran, Jenny Gorin, Joerge Ogorka
Publikováno v:
Journal of controlled release : official journal of the Controlled Release Society. 146(1)
Introduction Zoledronic acid (ZOL), a nitrogen-containing bisphosphonate, is a potent inhibitor of farnesyl-pyrophosphate synthase with poor in vitro cytotoxic activity as a result of its limited diffusion into tumor cells. The purpose of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13ee43fcc010815690a37d8a43149242
https://pubmed.ncbi.nlm.nih.gov/20462513
https://pubmed.ncbi.nlm.nih.gov/20462513
Publikováno v:
Molecular cancer therapeutics. 5(4)
The folate receptor is overexpressed in a broad spectrum of malignant tumors and represents an attractive target for selective delivery of anticancer agents to folate receptor–expressing tumors. This study examines folate-lipid conjugates as a mean
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29a4a9114151ee3a57bbc29940c5988f
https://pubmed.ncbi.nlm.nih.gov/16648551
https://pubmed.ncbi.nlm.nih.gov/16648551
Publikováno v:
Journal of drug targeting. 10(7)
Stealth (pegylated) liposomal doxorubicin (Doxil) has been extensively studied at the pre-clinical and clinical level in recent years. However, one issue not yet addressed is the effect of dose on tumor localization and therapeutic efficacy of Doxil.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::433ea32cf4395fa415d1039a2c3e0f59
https://pubmed.ncbi.nlm.nih.gov/12683721
https://pubmed.ncbi.nlm.nih.gov/12683721
Autor:
Gabizon, Alberto1,2 (AUTHOR) alberto.gabizon@gmail.com, Shmeeda, Hilary1 (AUTHOR), Draper, Benjamin3 (AUTHOR) benjamin.draper@ucl.ac.uk, Parente-Pereira, Ana3 (AUTHOR) anacatpp@gmail.com, Maher, John3 (AUTHOR) john.maher@kcl.ac.uk, Carrascal-Miniño, Amaia4 (AUTHOR) amaia.minino@kcl.ac.uk, de Rosales, Rafael T. M.4 (AUTHOR) rafael.torres@kcl.ac.uk, La-Beck, Ninh M.5 (AUTHOR) irene.la-beck@ttuhsc.edu
Publikováno v:
Pharmaceutics. Nov2023, Vol. 15 Issue 11, p2606. 20p.
Autor:
Shmeeda, Hilary1 (AUTHOR), Amitay, Yasmine1,2 (AUTHOR), Gorin, Jenny1 (AUTHOR), Tzemach, Dina1 (AUTHOR), Mak, Lidia1 (AUTHOR), Stern, Stephan T.3 (AUTHOR), Barenholz, Yechezkel2 (AUTHOR), Gabizon, Alberto1,2 (AUTHOR) alberto.gabizon@gmail.com
Publikováno v:
Journal of Drug Targeting. Nov2016, Vol. 24 Issue 9, p878-889. 12p.